Skip to main content
. 2014 Jul 9;14:500. doi: 10.1186/1471-2407-14-500

Table 6.

Prognostic scoring system providing probabilities of survival outcomes based on presence (+) or absence (-) of four criteria for improving patient selection for RFA treatment of liver-only CLM in the era of effective systemic therapies 1

 
  
 Clinical criteria
 Overall survival
 Recurrence-free survival
Score 2 Subgroup 3 Response 4 PR No. of CLM ≤ 3 Size of CLM 5  ≤ 3 cm CEA value ≤ 100 ng/mL median (months) 5-Years (%) median (months) 5-years (%)
0
  
 -
 -
 -
 -
 16
 0
 4
 0
1
 1A
 -
 -
 -
 +
 17
 0
 3
 0
 
 1B
 -
 -
 +
 -
 19
 0
 6
 0
 
 1C
 -
 +
 -
 -
 19
 0
 4
 0
 
 1D
 +
 -
 -
 -
 31
 0
 11
 0
2
 2A
 -
 -
 +
 +
 18
 0
 4
 0
 
 2B
 -
 +
 -
 +
 24
 0
 5
 0
 
 2C
 +
 -
 -
 +
 no
 no
 no
 no
 
 2D
 -
 +
 +
 -
 19
 0
 4
 0
 
 2E
 +
 -
 +
 -
 33
 0
 9
 0
 
 2 F
 +
 +
 -
 -
 36
 11
 10
 0
3
 3A
 -
 +
 +
 +
 27
 7
 5
 0
 
 3B
 +
 +
 -
 +
 44
 15
 9
 0
 
 3C
 +
 -
 +
 +
 40
 0
 11
 0
 
 3D
 +
 +
 +
 -
 44
 27
 11
 9
4   + + + + 46 39 13 22

Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; no, not observed; PR, partial remission; RFA, radiofrequency ablation.

1outcome probabilities are based on adjusted Kaplan-Meyer calculations in this study cohort (n = 88). 2score indicates the sum of present criteria. 3subgroups represent combinations of present and absent criteria in patients scoring 1–3. 4RECIST-defined response to the immediate preceding systemic therapy regimen before RFA treatment. 5after decrease of ≥30% in size following the immediate preceding systemic therapy regimen before RFA treatment.